Skip to main content
OpenTrials

Clinical trial condition

Recurrent Uterine Corpus Carcinoma

Explore clinical trials studying Recurrent Uterine Corpus Carcinoma. Study availability and eligibility vary by location and protocol.

30 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Uterine Corpus Carcinoma trial results

Completed

Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT01011933

Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, +1 more
Locations
  • Los Angeles County-USC Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of Colorado Cancer Center - Anschutz Cancer Pavilion Aurora, Colorado, United States
  • Hartford Hospital Hartford, Connecticut, United States
View all 72 locations
View Trial Details
Completed

Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer

NCT00729586

Conditions
Endometrial Carcinoma, Endometrial Neoplasms, Female Urogenital Diseases, +17 more
Locations
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center Burbank, California, United States
  • Stanford Cancer Institute Palo Alto, California, United States
  • University of California San Diego San Diego, California, United States
  • Colorado Gynecologic Oncology Group Aurora, Colorado, United States
View all 108 locations
View Trial Details
Completed

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

NCT01010126

Conditions
Adenocarcinoma, Adnexal Diseases, Adult Hepatocellular Carcinoma, +76 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Tower Cancer Research Foundation Beverly Hills, California, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Los Angeles County-USC Medical Center Los Angeles, California, United States
View all 61 locations
View Trial Details
Completed

Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer

NCT01098630

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, +28 more
Locations
  • Gynecologic Oncology Group of Arizona Phoenix, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center Burbank, California, United States
  • Roy and Patricia Disney Family Cancer Center Burbank, California, United States
View all 167 locations
View Trial Details
Completed

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT01642082

Conditions
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, +6 more
Locations
  • UCSF Medical Center-Mount Zion San Francisco, California, United States
  • Beebe Medical Center Lewes, Delaware, United States
  • Christiana Care Health System-Christiana Hospital Newark, Delaware, United States
  • Florida Hospital Orlando Orlando, Florida, United States
View all 30 locations
View Trial Details
Completed

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

NCT01210222

Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, +21 more
Locations
  • Hartford Hospital Hartford, Connecticut, United States
  • The Hospital of Central Connecticut New Britain, Connecticut, United States
  • Sarasota Memorial Hospital Sarasota, Florida, United States
  • Memorial University Medical Center Savannah, Georgia, United States
View all 33 locations
View Trial Details

Related conditions